The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.
 
Ofir Wolach
Honoraria - AbbVie; Astellas Pharma; Novartis
Consulting or Advisory Role - AbbVie; Astellas Pharma; Medison; Novartis; Pfizer; Teva
 
Pinkal Desai
Employment - Johnson & Johnson/Janssen (I)
Honoraria - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - Agios; Bristol-Myers Squibb/Celgene; Kura Oncology; Sanofi; SERVIER; Syndax; Takeda
Research Funding - Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Janssen Research & Development
Patents, Royalties, Other Intellectual Property - Detection of mutations in blood prior to leukemia
 
Evan Chen
Honoraria - Abbvie; Sermo
Consulting or Advisory Role - Guidepoint Global; Lumanity; Rigel
Research Funding - Abbvie
 
Joshua Zeidner
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Foghorn Therapeutics; Genentech; Genmab; Gilead Sciences; Immunogen; NeoGenomics Laboratories; Novartis; Sellas Life Sciences; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Faron Pharmaceuticals (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Loxo (Inst); Merck (Inst); Newave Pharmaceutical (Inst); Novartis (Inst); Sellas Life Sciences (Inst); Shattuck Labs (Inst); Stemline Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Zentalis (Inst)
 
Thomas LeBlanc
Stock and Other Ownership Interests - Dosentrx; Thyme Care
Honoraria - Genentech; Lilly
Consulting or Advisory Role - Abbvie/Genentech; Agios/Servier; Apellis Pharmaceuticals; Astellas Pharma; Bristol-Myers Squibb/Celgene; Gilead Sciences; GlaxoSmithKline; Menarini Group; Novartis; Pfizer
Speakers' Bureau - Abbvie; Bristol-Myers Squibb/Celgene; Daiichi-Sankyo; Geron; GlaxoSmithKline; Incyte; Menarini; Rigel; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Inc., royalty
Travel, Accommodations, Expenses - Abbvie/Genentech; Astellas Pharma; Bristol-Myers Squibb/Celgene; Incyte; Menarini; Rigel; SERVIER
 
Sameem Abedin
Consulting or Advisory Role - AbbVie; Astellas Pharma; Novartis
Research Funding - Actinium Pharmaceuticals; AltruBio; Incyte
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; Disc Medicine; Genentech/Roche; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Merck; Merck; MorphoSys; Novartis; Novartis; Pfizer; SERVIER; SOBI; Stemline Therapeutics; Stemline Therapeutics; Takeda
Speakers' Bureau - Blueprint Medicines; Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Board member: Alabama Cancer Congress
 
Kendra Sweet
Consulting or Advisory Role - TBD
 
Yakir Moshe
Honoraria - AbbVie; Astellas Pharma; Medison; Novartis; Pfizer; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Astellas Pharma; Medison; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AbbVie
 
Daniel Pollyea
Consulting or Advisory Role - AbbVie; Adicet Bio; Aptevo Therapeutics; Arcellx; AstraZeneca; Beigene; BerGenBio; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Hibercell; Immunogen; Jazz Pharmaceuticals; Kura Oncology; LINK Medical; Magenta Therapeutics; Medivir; Novartis; OncoVerity; Qihan Biotech; Rigel; Ryvu Therapeutics; Seres Therapeutics; Sumitomo; Syros Pharmaceuticals; Zentalis
Research Funding - AbbVie; Bristol-Myers Squibb; Karyopharm Therapeutics; Teva
 
Catherine Lai
Honoraria - OncLive
Consulting or Advisory Role - Abbvie; Astellas Pharma; BioAscent; Daiichi Sankyo/Lilly; Genentech; Jazz Pharmaceuticals; Macrogenics; Novartis; PDS Biotechnology; Pfizer; Taiho Oncology
Research Funding - bristol meyers squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Marina Konopleva
Consulting or Advisory Role - AbbVie; Adaptive Biotechnologies; Curis; Dark Blue Therapeutics; JNJ/Janssen; MEI Pharma; Menarini/Stemline Therapeutics; Novartis; Sanofi; Servier; Syndax
Research Funding - Abbvie; JNJ/Janssen; Klondike
 
Boaz Nachmias
Consulting or Advisory Role - AbbVie; Astellas Pharma; Medison
 
Lee Mozessohn
Consulting or Advisory Role - AbbVie
 
Marin Xavier
Consulting or Advisory Role - AbbVie/ Genmab/Pharmacyclics; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Geron; GlaxoSmithKline; Lily/Loxo; Morphosys/Incyte Corporation
Speakers' Bureau - AbbVie/ Genmab/Pharmacyclics; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Geron; GlaxoSmithKline; Lily/Loxo; Morphosys/Incyte Corporation
 
Tsila Zuckerman
Honoraria - AbbVie; BioSight; Cellect Biotechnology; Gilead Sciences; Janssen; Novartis; Orgenesis
 
Yanqing Xu
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Chia-Wei Lin
Employment - Genentech
Stock and Other Ownership Interests - Genentech; Roche
 
Rebecca Burne
Employment - Analysis Group
 
Aaron Goldberg
Honoraria - AbbVie; DAVA Oncology; Kura Oncology
Consulting or Advisory Role - AbbVie; Astellas Pharma; Bristol-Myers Squibb; Ikena Oncology; Molecular Partners; Remedy Plan Therapeutics; Syndax
Research Funding - Abbvie; Aprea AB; Aptose Biosciences; AROG; Kura Oncology; Pfizer; Prelude Therapeutics